SCHEMBL20135495

SCHEMBL20135495

Cc1cc(C)c(N2CCN(C(=O)c3ccc(C4(C(C)(C)C)NC(=O)NC4=O)cc3)CC2)nc1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
MAPK1 P28482 1/20 0.38
ADAMTS5 Q9UNA0 2/20 0.37
GBA1 P04062 3/20 0.36
CRBN Q96SW2 2/20 0.36
HTT P42858 4/20 0.35
SMN1; SMN2 Q16637 5/20 0.35
LMNA P02545 3/20 0.35
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
HIF1A Q16665 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
SLC6A7 Q99884 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TSHR P16473 1/20 0.35
USP2 O75604 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
ADAM17 P78536 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688401 1.00 ALDH1A1 (0.38) ALDH1A1MAPK1ADAMTS5GBA1CRBN
SCHEMBL29688860 0.92 ALDH1A1 (0.36) ALDH1A1MAPK1ADAMTS5CRBNHTT
SCHEMBL20135008 0.92 ALDH1A1 (0.36) ALDH1A1MAPK1ADAMTS5CRBNHTT
SCHEMBL20135567 0.89 ADAM17 (0.36) ALDH1A1MAPK1ADAMTS5GBA1SMN1; SMN2
SCHEMBL20134799 0.86 ALDH1A1 (0.39) ALDH1A1MAPK1ADAMTS5GBA1CRBN
SCHEMBL29688482 0.86 ALDH1A1 (0.39) ALDH1A1MAPK1ADAMTS5GBA1CRBN
SCHEMBL20134796 0.86 ALDH1A1 (0.39) ALDH1A1MAPK1ADAMTS5GBA1CRBN
SCHEMBL29688956 0.86 ALDH1A1 (0.40) ALDH1A1MAPK1ADAMTS5CRBNHTT
SCHEMBL20135515 0.86 ALDH1A1 (0.40) ALDH1A1MAPK1ADAMTS5CRBNHTT
SCHEMBL20135512 0.85 SLC6A7 (0.38) ALDH1A1MAPK1GBA1CRBNHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 ALDH1A1 584/4885MAPK1 377/4885ADAMTS5 23/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 ALDH1A1 610/4885MAPK1 270/4885ADAMTS5 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.